Latest Ratios: P/E Ratio -0.5x · EV/EBITDA N/A · ROE -138.8%. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $10M | $13M | $19M | $67M | $51M | $436M | $399M | $56M | $23M | $21M | $409M |
| Enterprise Value | $7M | $10M | $2M | $44M | $36M | $401M | $277M | $41M | $35M | $24M | $403M |
| P/E Ratio → | -0.46 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.09 | 1.38 | 1.77 | 6.73 | 5.05 | 40.93 | 36.79 | 5.64 | 2.19 | 2.11 | 54.33 |
| P/B Ratio | 0.64 | 2.38 | — | 3.43 | 1.10 | 4.81 | 3.05 | — | — | 0.87 | 13.97 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.01 | 0.21 | 4.35 | 3.51 | 37.65 | 25.53 | 4.11 | 3.33 | 2.44 | 53.51 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.5% | 99.5% | 99.1% | 97.9% | 97.5% | 95.0% | 95.1% | 95.0% | 94.6% | 95.0% | 94.7% |
| Operating Margin | -348.4% | -348.4% | -408.3% | -482.2% | -521.7% | -395.0% | -229.8% | -243.5% | -281.3% | -502.7% | -771.1% |
| Net Profit Margin | -80.3% | -80.3% | -397.8% | -473.0% | -557.7% | -426.7% | -276.0% | -321.3% | -312.4% | -538.7% | -802.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -138.8% | -138.8% | -634.7% | -143.2% | -82.6% | -41.0% | -61.8% | — | -334.2% | -200.2% | -128.8% |
| ROA | -24.8% | -24.8% | -73.2% | -50.9% | -41.8% | -24.8% | -25.0% | -88.7% | -58.6% | -81.1% | -79.1% |
| ROIC | — | — | — | -272.4% | -91.9% | -97.9% | — | — | -127.1% | -148.2% | -110.7% |
| ROCE | -233.9% | -233.9% | -114.9% | -62.7% | -42.8% | -24.5% | -22.3% | -81.8% | -64.7% | -91.5% | -84.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.30 | 0.30 | — | 0.14 | 0.08 | 0.06 | 0.06 | — | — | 1.73 | 0.68 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.63 | — | -1.21 | -0.34 | -0.39 | -0.93 | — | — | 0.14 | -0.21 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -2.47 | -2.47 | -69.55 | -22.48 | -10.88 | -9.16 | -4.87 | -5.63 | -7.30 | -12.44 | -20.75 |
Net cash position: cash ($5M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.49 | 0.49 | 1.39 | 2.77 | 9.20 | 9.11 | 17.14 | 3.82 | 4.25 | 4.56 | 5.44 |
| Quick Ratio | 0.49 | 0.49 | 1.39 | 2.77 | 9.20 | 9.11 | 17.14 | 3.82 | 4.38 | 4.56 | 5.59 |
| Cash Ratio | 0.36 | 0.36 | 1.05 | 2.56 | 8.55 | 8.62 | 16.72 | 3.14 | 3.81 | 4.27 | 5.16 |
| Asset Turnover | — | 0.47 | 0.26 | 0.13 | 0.09 | 0.07 | 0.05 | 0.28 | 0.28 | 0.13 | 0.13 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 112.06 | 101.75 | 106.86 | 110.50 | 102.51 | 118.36 | 100.25 | 113.32 | 119.24 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $658201 | $315314 | $264664 | $233481 | $228922 | $121675 | $82951 | $82795 | $14913 | $66392 |
Imminent liquidity exhaustion
As reported in recent financial filings, Curis trades at a price-to-sales ratio of 6.41, a multiple that appears disconnected from the company's negative revenue growth and suggests investors are pricing in speculative binary outcomes rather than the underlying fundamental value of the current royalty-based revenue stream.
The lack of a positive P/E ratio or meaningful EV/EBITDA metrics underscores the market's focus on clinical trial success as the sole driver of future value. Investors should monitor whether this valuation premium holds as the cash runway continues to tighten, potentially forcing dilutive equity raises that would further compress existing shareholder value.
Based on historical data, Curis has demonstrated a persistent decay in return on invested capital, with figures reaching -16.3% in 2026Q1, indicating that the company's heavy R&D spending is failing to generate productive returns on the capital deployed into its hematologic malignancy pipeline.
The negative ROIC trend suggests that the company is effectively destroying value with every dollar spent on clinical development. This trend warrants further investigation into whether the current pipeline assets possess the commercial potential to eventually reverse this trajectory or if the capital structure is fundamentally misaligned with the company's long-term growth prospects.
According to quarterly reports, Curis's asset turnover ratio has remained consistently low, hovering near 0.05 to 0.11, which highlights the company's inability to leverage its asset base into meaningful revenue generation outside of passive royalty streams from legacy partnerships.
The lack of operational efficiency is compounded by the absence of a commercial manufacturing engine, leaving the company entirely dependent on external capital. The volatility in payables and the lack of a clear cash conversion cycle suggest that management's focus remains on survival rather than optimizing the efficiency of its limited operational resources.
As indicated by the most recent financial statements, the company's current ratio has deteriorated to 1.00, a significant decline from historical peaks, which suggests that Curis is increasingly vulnerable to even minor disruptions in its cash inflows or unexpected increases in clinical trial expenditures.
The rapid depletion of cash reserves to $5.06M leaves little room for error, making the company highly susceptible to liquidity stress. Investors should monitor the company's ability to secure non-dilutive funding, as the current liquidity position appears insufficient to support the long-term clinical development of its primary assets without immediate intervention.
The price-to-sales ratio is frequently misapplied to Curis, as it obscures the fact that the company's revenue is derived from passive royalties rather than core operational sales, rendering the metric an unreliable indicator of the company's true earning power or its ability to sustain clinical operations.
Analysts should instead focus on the 'cash runway to milestone' ratio, which provides a more accurate assessment of the company's survival risk. Relying on P/S multiples ignores the structural reality that Curis is a clinical-stage entity where revenue is a byproduct of legacy assets rather than a reflection of current operational success.
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CRIS stock.
Curis, Inc.'s current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
Curis, Inc.'s return on equity (ROE) is -138.8%. The historical average is -89.4%.
Based on historical data, Curis, Inc. is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Curis, Inc. has 99.5% gross margin and -348.4% operating margin.